Medical/Pharmaceuticals
New CAS BioFinder Discovery Platform empowers drug discovery scientists to reveal insights, drive innovation, and save time
Transformative new scientific information capabilities combine an unparalleled collection of curated science data with advanced predictive models to accelerate early-stage drug discovery innovation COLUMBUS, Ohio, May 21, 2024 /PRNewswire/ -- Today, CAS, a division of the American Chemical Socie...
2024-05-21 21:00
2230
Complete Genomics expands to East Coast with new Customer Experience Center in Greater Boston's Biotech Hub
The laboratory gives researchers a training ground for state-of-the-art DNBSEQ technology to further precision diagnostics and treatments SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, today announced theMay 22 opening of its Customer E...
2024-05-21 21:00
1726
Etiometry Awarded Frost & Sullivan's 2024 North American Enabling Technology Leadership Award for Leading Innovation in Clinical Decision Support Systems
Etiometry's solutions provide healthcare professionals with actionable intelligence, setting new benchmarks in critical care treatment. SAN ANTONIO, May 21, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the clinical decision support for critical care industry and, based on its findin...
2024-05-21 20:00
1478
Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy
SUZHOU, China, May 21, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, RAG-01, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This notable a...
2024-05-21 20:00
1673
Cali Biosciences Announces Publication of Successful Phase 2 Study Results in Hernia
SAN DIEGO, May 21, 2024 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biotechnology company dedicated to the research and development of innovative drugs, announced publication of "CPL‑01, an investigational long‑acting ropivacaine, demonstrates saf...
2024-05-21 17:52
1075
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
YANTAI, China, May 21, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
2024-05-21 17:35
1754
Dignitana signs an exclusivity agreement for Japan with Konica Minolta
LUND, Sweden, May 21, 2024 /PRNewswire/ -- Dignitana has signed a new multi-year Distribution Agreement for technology market leaderKonica Minolta to be the exclusive provider of The DigniCap Scalp Cooling System inJapan. DigniCap Delta is an innovative medical device used by cancer centers to m...
2024-05-21 16:43
1347
BGI Team Successfully Reaches the Summit of Mount Everest
Sends the world's first ultrasound image and EEG data from the top of the world SHENZHEN, China, May 21, 2024 /PRNewswire/ -- BGI Group Chairman and Co-Founder,Wang Jian, and a scientific team from BGI today reached the summit of Mount Everest (Qomolangma) at 8,848.86 meters and, using handheld u...
2024-05-21 16:41
1574
NUS scientists discover a novel way of activating muscle cells' natural defences against cancer using magnetic pulses
This drug-free, non-invasive approach could open the doors for new developments in cancer therapy and cancer biomarker discovery SINGAPORE, May 21, 2024 /PRNewswire/ -- A team of researchers led by Associate Professor Alfredo Franco-Obregón from the NUS Institute for Health Innovation & Technolo...
2024-05-21 16:35
1519
Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024
NANJING, China, May 21, 2024 /PRNewswire/ -- The 10th European Stroke Organization Congress (ESOC), held inBasel, Switzerland from May 15 to 17, 2024 , showcased six studies on Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection) and a new dosage form of sublingual tablets unde...
2024-05-21 15:52
1304
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
YONGIN, South Korea, May 21, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A. With this FDA clearance,...
2024-05-21 15:12
1419
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis
* Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab[1],[2] * Data from a post-hoc analysis of the LIBERTY-CD study showed that, despite affecting drug lev...
2024-05-21 12:01
1711
ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals
SEOUL, South Korea, May 21, 2024 /PRNewswire/ -- Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the " Company") and has been supportive of the Company's mission since 2...
2024-05-21 09:49
1494
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and ot...
2024-05-21 08:55
2319
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
* CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. * Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer...
2024-05-21 07:58
1516
Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA
* First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration * The BLA is supported by data from the pivotal Phase 3 ALLELE study which was investigating Tab-cel in relapsed or refractory EBV+ PTLD following solid organ transplant (SOT) or hematopoietic cell transpla...
2024-05-20 21:30
2047
Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite
- From research to real-world impact: Lunit demonstrates Lunit INSIGHT's clinical safety, effectiveness, and efficiency in 100 papers SEOUL, South Korea, May 20, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...
2024-05-20 21:00
2013
Duoning Collaborates with Bioelectronica to Commercialize a Single-Cell Sorting System for Antibody Discovery
SHANGHAI, May 20, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning"), a leading one-stop bioprocess provider inChina, today announced a strategic partnership with Bioelectronica, a company focusing on developing tools for single-cell/single-bacteria research. This partnership aims to en...
2024-05-20 20:00
1791
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLog...
2024-05-20 18:00
1664
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
BORDEAUX, France, May 20, 2024 /PRNewswire/ -- TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1] Par...
2024-05-20 14:30
1690
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6494
